Zacks Research Forecasts Increased Earnings for Haemonetics

Key Points

• Zacks Research has raised its Q1 2028 earnings per share (EPS) estimate for Haemonetics from $1.44 to $1.45, with a full-year consensus EPS estimate set at $4.55.
• The stock has received mixed ratings from analysts, including a market outperform rating from JMP Securities and a neutral rating from JPMorgan Chase & Co., with an average price target of $82.50.
• Haemonetics reported $1.10 EPS for the last quarter, exceeding analyst expectations of $1.01, despite revenue declining by 4.4% year-over-year.

Haemonetics Corporation (NYSE:HAE - Free Report) - Stock analysts at Zacks Research lifted their Q1 2028 EPS estimates for shares of Haemonetics in a research note issued to investors on Monday, September 8th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings of $1.45 per share for the quarter, up from their previous forecast of $1.44. The consensus estimate for Haemonetics' current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics' FY2028 earnings at $5.83 EPS.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.09. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The company had revenue of $321.39 million during the quarter, compared to analysts' expectations of $305.12 million. During the same period in the prior year, the business earned $1.02 EPS. The firm's quarterly revenue was down 4.4% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS.

Other equities analysts have also issued research reports about the company. Raymond James Financial lowered Haemonetics from a "strong-buy" rating to an "outperform" rating and decreased their price target for the company from $105.00 to $78.00 in a research note on Monday, August 11th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $62.00 price objective (down from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Needham & Company LLC reiterated a "buy" rating and issued a $68.00 target price (down previously from $84.00) on shares of Haemonetics in a report on Thursday, August 7th. Baird R W raised Haemonetics to a "strong-buy" rating in a research report on Wednesday, June 25th. Finally, Mizuho lowered their price target on Haemonetics from $90.00 to $70.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Haemonetics has a consensus rating of "Moderate Buy" and a consensus target price of $78.78.

Haemonetics Trading Down 2.0%

NYSE:HAE traded down $1.03 on Wednesday, hitting $51.17. The stock had a trading volume of 565,420 shares, compared to its average volume of 814,846. The company has a fifty day moving average price of $63.77 and a two-hundred day moving average price of $65.38. Haemonetics has a 1-year low of $50.68 and a 1-year high of $94.99. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04. The stock has a market cap of $2.47 billion, a price-to-earnings ratio of 15.65, a PEG ratio of 0.96 and a beta of 0.39.

Institutional Investors Weigh In On Haemonetics

A number of hedge funds have recently bought and sold shares of HAE. Quarry LP grew its position in shares of Haemonetics by 63.4% during the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 192 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock worth $31,000 after acquiring an additional 396 shares during the last quarter. GAMMA Investing LLC grew its holdings in Haemonetics by 59.4% during the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier's stock worth $33,000 after acquiring an additional 165 shares in the last quarter. UMB Bank n.a. increased its position in shares of Haemonetics by 91.7% in the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier's stock valued at $50,000 after purchasing an additional 320 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of Haemonetics in the 2nd quarter valued at $64,000. Institutional investors and hedge funds own 99.67% of the company's stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.